Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Next Previous
Trial Profile

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zenocutuzumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver metastases; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus First in man; Registrational; Therapeutic Use
  • Acronyms eNRGy
  • Sponsors Merus

Most Recent Events

  • 05 Feb 2025 According to a Merus media release,the New England Journal of Medicine (NEJM) published results of the registrational phase 2 eNRGy trial (n=204) for Bizengri (zenocutuzumab), for adults with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor NRG1 gene fusion who have disease progression on or after prior systemic therapy.
  • 05 Feb 2025 According to partner therapeutics media release, the New England Journal of Medicine (NEJM) published results of the 204-patient, global, multicenter, single-arm, Phase 2 clinical trial of zenocutuzumab-zbco (BIZENGRI)
  • 05 Feb 2025 Results presented in the partner therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top